Nicole Cimbak
Brigham and Women's Hospital
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Nicole Cimbak.
Gynecologic Oncology | 2016
Larissa J. Lee; Brooke E. Howitt; Paul J. Catalano; C. Tanaka; Rita Murphy; Nicole Cimbak; Rebecca DeMaria; Paula Bu; Christopher P. Crum; Neil S. Horowitz; Ursula A. Matulonis; Akila N. Viswanathan
OBJECTIVE HPV status is an important prognostic factor for patients with oropharyngeal, anal and cervical cancers treated with radiotherapy. This study evaluates the association between HPV and p16 status and outcome in a radiation-treated cohort with vulvar squamous cell carcinoma (SCC). METHODS Patients with vulvar SCC who received radiotherapy with or without surgical resection between 1985 and 2011 were identified retrospectively. Immunostaining for p16 and multiplex PCR for HPV genotyping were performed using archival tumor tissue from 57 patients. Actuarial estimates of PFS, OS and in-field recurrence were calculated using the Kaplan-Meier method. Cox proportional hazards models were used for multivariable analysis. Median follow-up was 58months among the 57 patients with an available tumor specimen. RESULTS HPV prevalence was implied in 37% by (diffuse linear) p16 immunostaining and confirmed in 27% by HPV PCR with good agreement (κ=0.7). HPV-16 was identified in 80% of HPV-positive tumors. Women with p16-positive tumors had significantly higher 5-year PFS (65% vs. 16%, p<0.01) and OS (65% vs. 22%, p=0.01) rates, as well as lower in-field relapse rates (19% vs. 75%, p<0.01) compared to those with p16-negative disease. On multivariable analysis adjusted for age and stage, p16 positivity was significantly associated with better PFS (HR 0.4, 95% CI 0.2-0.9) and lower rates of in-field relapse (HR 0.2, 95% CI 0.06-0.6). Results were similar when analyzed by HPV DNA status. CONCLUSION In this study, the presence of HPV or its surrogate of p16 immunostaining was an independent prognostic factor for in-field relapse and survival in women with vulvar SCC treated with radiotherapy. This finding warrants validation in larger cohorts or the prospective setting.
Journal of Gynecologic Oncology | 2016
Devarati Mitra; Paul J. Catalano; Nicole Cimbak; Antonio L. Damato; Michael G. Muto; Akila N. Viswanathan
Objective Lower extremity lymphedema adversely affects quality of life by causing discomfort, impaired mobility and increased risk of infection. The goal of this study is to investigate factors that influence the likelihood of lymphedema in patients with endometrial cancer who undergo adjuvant radiation with or without chemotherapy. Methods A retrospective chart review identified all stage I–III endometrial cancer patients who had a hysterectomy with or without complete staging lymphadenectomy and adjuvant radiation therapy between January 2006 and February 2013. Patients with new-onset lymphedema after treatment were identified. Logistic regression was used to find factors that influenced lymphedema risk. Results Of 212 patients who met inclusion criteria, 15 patients (7.1%) developed new-onset lymphedema. Lymphedema was associated with lymph-node dissection (odds ratio [OR], 5.6; 95% CI, 1.01 to 105.5; p=0.048) and with the presence of pathologically positive lymph nodes (OR, 4.1; 95% CI, 1.4 to 12.3; p=0.01). Multivariate logistic regression confirmed the association with lymph-node positivity (OR, 3.2; 95% CI, 1.0007 to 10.7; p=0.0499) when controlled for lymph-node dissection. Median time to lymphedema onset was 8 months (range, 1 to 58 months) with resolution or improvement in eight patients (53.3%) after a median of 10 months. Conclusion Lymph-node positivity was associated with an increased risk of lymphedema in endometrial cancer patients who received adjuvant radiation. Future studies are needed to explore whether node-positive patients may benefit from early lymphedema-controlling interventions.
Brachytherapy | 2015
Lindsay C. Brown; Ivy A. Petersen; Michael G. Haddock; Jamie N. Bakkum-Gamez; Larissa J. Lee; Nicole Cimbak; Ross S. Berkowitz; Akila N. Viswanathan
OBJECTIVE Uterine carcinosarcoma (CS) is an aggressive malignancy and the optimal adjuvant treatment is not well-established. We report outcomes with vaginal brachytherapy (VB) for women with early-stage CS. METHODS AND MATERIALS A multi-institutional retrospective study of Stage I-II CS treated with hysterectomy, surgical staging, and adjuvant high-dose-rate VB without external-beam pelvic radiotherapy was performed. Rates of vaginal control, pelvic control, locoregional control, disease-free survival, and overall survival were determined using the Kaplan-Meier method. RESULTS 33 patients were identified. Prescribed VB dose was 21 Gy in three fractions (n = 15 [45%]) or 24 Gy in six fractions (n = 18 [55%]). Eighteen patients (55%) received chemotherapy. Median followup was 2.0 years. Twenty-seven patients (82%) underwent pelvic lymphadenectomy, 5 (15%) had nodal sampling, and 1 (3%) had no lymph node assessment. Relapse occurred in 11 patients (33%), all of whom had lymph node evaluation. Locoregional relapse was a component of failure in 6 patients (18%), of whom 3 (9%) failed in the pelvis alone. Three patients (9%) had simultaneous distant and locoregional relapse (two vaginal, one pelvic). Five additional patients (15%) had distant relapse. Six of the 11 patients (55%) with disease recurrence received chemotherapy. Two-year vaginal control and pelvic control were 94% and 87%. Two-year locoregional control, disease-free survival, and overall survival were 81%, 66%, and 79%. CONCLUSIONS Despite having early-stage disease and treatment with VB, patients in this series had relatively high rates of local and distant relapse. Patients who undergo lymphadenectomy and VB remain at risk for relapse. Novel treatment strategies are needed.
Radiotherapy and Oncology | 2015
Devarati Mitra; Remi A. Nout; Paul J. Catalano; Carien L. Creutzberg; Nicole Cimbak; Larissa J. Lee; Akila N. Viswanathan
International Journal of Radiation Oncology Biology Physics | 2014
Ryan James Bair; Nicole Cimbak; C. Wakefield; Eric Bair; Akila N. Viswanathan
Brachytherapy | 2014
Lindsay C. Brown; Ivy A. Petersen; Michael G. Haddock; Larissa J. Lee; Nicole Cimbak; Akila N. Viswanathan
Journal of Clinical Oncology | 2017
Larissa J. Lee; Brooke E. Howitt; Esther Oliva; Hongkai Zhang; Paul J. Catalano; Christopher P. Crum; Paula Bu; Nicole Cimbak; Rebecca DeMaria; Rita Murphy; Neil S. Horowitz; Ursula A. Matulonis; Andrea L. Russo
International Journal of Radiation Oncology Biology Physics | 2014
Devarati Mitra; Nicole Cimbak; Larissa J. Lee; Akila N. Viswanathan
International Journal of Radiation Oncology Biology Physics | 2014
Larissa J. Lee; Rita Murphy; Nicole Cimbak; Christopher P. Crum; C. Gasper; Akila N. Viswanathan
International Journal of Radiation Oncology Biology Physics | 2014
Larissa J. Lee; Rita Murphy; Nicole Cimbak; Akila N. Viswanathan